Fatty liver disease (MASLD): the silent, often reversible condition
Fatty liver disease, now called MASLD (metabolic dysfunction-associated steatotic liver disease), is extra fat stored inside the liver in someone who has a metabolic risk factor such as excess waist fat, raised blood sugar or high blood pressure. It is extremely common, affecting roughly one in five UK adults and around 30 percent of people worldwide, and it usually causes no symptoms at all. The crucial point is that the early stage is often reversible: losing around 7 to 10 percent of body weight, moving more, and cutting alcohol and added sugar can clear fat from the liver and, in many people, reverse the early damage.
What MASLD is, and why the name changed
Your liver normally holds very little fat. When more than about 5 percent of its weight is fat, that is steatosis, or a fatty liver. In most cases this is driven by the same metabolic problems behind type 2 diabetes and heart disease, not by alcohol. For decades the condition was called non-alcoholic fatty liver disease (NAFLD), a label defined by what it was not.
In 2023 a panel of more than 200 specialists, led by Mary Rinella and colleagues across the American, European and Latin American liver associations, used a formal Delphi consensus process to rename it.1 Around three quarters of the panel backed a change. Two reasons stood out: the word "non-alcoholic" defined the disease by absence rather than cause, and many felt the old name trivialised a serious condition and could make patients feel blamed.1 The new term, MASLD, names the actual driver, metabolic dysfunction. The more advanced inflammatory form, once called NASH (non-alcoholic steatohepatitis), is now MASH (metabolic dysfunction-associated steatohepatitis).1
Crucially, MASLD is not just a renaming. It comes with a positive definition: fat in the liver plus at least one of five cardiometabolic risk factors.1 This ties it firmly to the cluster of problems known as metabolic syndrome, and to insulin resistance, which is the engine underneath most cases.
| Risk factor | Threshold (adults) |
|---|---|
| Overweight or central obesity | BMI 25 or above (23 in Asian populations), or raised waist circumference |
| Raised blood glucose | Fasting glucose 5.6 mmol/L or above, HbA1c 5.7 percent or above, or type 2 diabetes |
| Raised blood pressure | 130/85 mmHg or above, or on treatment |
| Raised triglycerides | 1.70 mmol/L or above, or on lipid-lowering treatment |
| Low HDL cholesterol | Below 1.0 mmol/L (men) or 1.3 mmol/L (women), or on treatment |
Key facts
- MASLD affects roughly 30 percent of adults globally and around 1 in 5 in the UK, making it the most common liver condition in the country.2
- It is usually silent. Most people have no symptoms, and the British Liver Trust estimates that around 4 in 5 people with the advanced form are undiagnosed.2
- More than 80 percent of people with fatty liver have normal routine liver blood tests, so a normal ALT does not rule it out.3
- In a study of 293 people with biopsy-proven steatohepatitis, everyone who lost 10 percent or more of their weight had reduced liver injury, 90 percent had resolution of steatohepatitis, and 45 percent had regression of fibrosis.4
- The first-line NHS test for liver scarring is a simple calculation, the FIB-4 score, from your age and three routine blood results.3
How it is found: ALT, ultrasound and the FIB-4 score
Because MASLD is silent, it is usually picked up by accident: a fatty liver spotted on an abdominal ultrasound done for something else, or a mildly raised liver enzyme called ALT (alanine aminotransferase) on a blood test. Both are useful flags, but both are unreliable on their own. Most people with MASLD have a normal ALT, and NICE is explicit that normal liver blood tests should not be used to rule the condition out.3
What matters far more than the fat itself is whether the liver has started to scar. That is where the FIB-4 score comes in. It combines your age with three routine blood results (the enzymes AST and ALT, and your platelet count) to estimate the risk of advanced fibrosis. It costs nothing extra, and under the NICE pathway it is the first-line test in primary care.35 A low score is reassuring; an indeterminate or high score leads to a second test, such as the Enhanced Liver Fibrosis (ELF) blood test or a FibroScan, which measures liver stiffness.5
A useful mental model: a fatty liver is the smoke, fibrosis is the fire. Steatosis tells you there is a metabolic problem, but it is the amount of scarring that predicts serious liver outcomes. This is why the FIB-4 score, not the ultrasound report, drives what happens next.
The spectrum: from simple fat to scarring
MASLD is not one fixed state but a spectrum, and where you sit on it matters enormously.
- Simple steatosis: fat in the liver with little or no inflammation. This is the most common stage and carries a relatively low risk of progressing to serious liver disease.
- Steatohepatitis (MASH): fat plus inflammation and injury to liver cells. This is the stage that drives scarring.
- Fibrosis: scar tissue laid down in response to ongoing injury, graded from F1 to F4.
- Cirrhosis (F4): advanced, widespread scarring that can lead to liver failure and liver cancer.
Most people never progress beyond the first stage. But because the condition is common, even a small percentage progressing adds up to a large number of people, and fibrosis stage is the single strongest predictor of liver-related death.6 The encouraging flip side is that fibrosis is not necessarily a one-way street: in the right conditions, early scarring can regress.4
Why it happens: insulin resistance and metabolic syndrome
The underlying mechanism is the same insulin resistance that precedes type 2 diabetes. When muscle and fat cells stop responding well to insulin, fatty acids flood out of overloaded fat stores into the liver, while high insulin switches on de novo lipogenesis, the liver's own production of new fat.7 The liver becomes a fat depot it was never meant to be. This is why MASLD travels with the rest of metabolic syndrome (central weight gain, high blood pressure, abnormal lipids and rising blood sugar) and why it raises cardiovascular risk. For most people with MASLD, a heart attack is a more likely outcome than liver failure.
This mechanism also explains the most effective treatment. Remove the surplus energy and the ectopic fat that comes with it, and the liver clears. The same levers that reverse early insulin resistance reverse early fatty liver.
The strong evidence that early disease is reversible
This is the genuinely hopeful part, and the evidence is unusually clear for a lifestyle intervention.
Weight loss of around 7 to 10 percent
The landmark study is from Eduardo Vilar-Gomez and colleagues, published in Gastroenterology in 2015. They followed 293 people with biopsy-proven steatohepatitis through 52 weeks of lifestyle change, with liver biopsies before and after.4 The results scaled cleanly with weight loss. Everyone who lost 10 percent or more of their body weight had reduced liver injury, 90 percent had resolution of steatohepatitis, and 45 percent had regression of fibrosis.4 Those who lost 7 to 10 percent also saw their liver injury scores fall.4 This is why guidelines, including the 2024 European EASL-EASD-EASO guideline, set a target of around 7 to 10 percent weight loss.6
Evidence note: The Vilar-Gomez study is a large, prospective, biopsy-confirmed study, which is strong evidence that weight loss changes liver tissue, not just blood markers. It was a single-arm cohort rather than a randomised controlled trial, and only a minority of people reached the 10 percent target, which is the honest limitation: the result is impressive but hard to achieve and sustain.
Exercise, even without much weight loss
Physical activity helps liver fat partly independently of the scales. A systematic review and meta-analysis by Shelley Keating and colleagues found that structured exercise, both aerobic and resistance training, reduced liver fat even when weight barely changed.8 The practical reading is to combine regular aerobic activity with two or three resistance sessions a week, which is also the approach we lay out in the stack builder.
Cutting alcohol and added sugar
Even though MASLD is defined as not primarily alcohol-driven, alcohol still adds insult to an already stressed liver, and guidelines advise reducing it, particularly where there is any fibrosis.6 Added sugar, especially fructose from sugary drinks, is a specific problem because fructose is a direct fuel for de novo lipogenesis. In a randomised controlled trial in 94 healthy men, sugar-sweetened drinks providing fructose or sucrose increased the liver's fat production, an effect not seen with glucose.9 European guidelines now advise a Mediterranean-style diet, limiting ultra-processed food and avoiding sugar-sweetened drinks.6
A note on speed and medication: aim for gradual weight loss of around 0.5 to 1 kg a week. Very rapid crash dieting can occasionally worsen liver inflammation. If you take insulin or other diabetes medication, or blood-pressure tablets, doses may need adjusting as you lose weight, so do this with your GP rather than alone. Newer weight-loss medicines and a dedicated MASH drug have emerged, but these are prescribed decisions, not first steps. None of this is medical advice.
What to ask your GP
What to ask your GP
- I have a fatty liver on a scan (or risk factors for one). Can we calculate my FIB-4 score to check for liver scarring?5
- If my FIB-4 is raised or indeterminate, can I have a second test such as an ELF blood test or a FibroScan?5
- Should we also check my HbA1c, full lipid panel and blood pressure, given the strong link with heart and metabolic risk?
- Are there other causes we should exclude, such as alcohol intake, certain medications, or viral hepatitis?
- If I lose weight quickly, will any of my current medications need adjusting?
What to do next
References
- Rinella ME, Lazarus JV, Ratziu V, et al., 2023. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78(6):1966-1986. link
- British Liver Trust. MASLD, NAFLD and fatty liver disease; Fatty liver disease: the silent epidemic. link
- National Institute for Health and Care Excellence (NICE), 2016 (updated). Non-alcoholic fatty liver disease (NAFLD): assessment and management. NICE guideline NG49. link
- Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al., 2015. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149(2):367-378. link
- Srivastava A, Gailer R, Tanwar S, et al., 2019. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease (FIB-4 then ELF). Journal of Hepatology; see also NICE NG49 fibrosis testing. link
- European Association for the Study of the Liver (EASL), EASD, EASO, 2024. Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology. link
- Sanyal AJ, et al.; see Younossi ZM, et al., 2018. Global epidemiology and pathophysiology of NAFLD. Hepatology / StatPearls: Metabolic Dysfunction-Associated Steatotic Liver Disease. link
- Keating SE, Hackett DA, George J, Johnson NA, 2012. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of Hepatology 57(1):157-166. link
- Geidl-Flueck B, Hochuli M, Nemeth A, et al., 2021. Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: a randomized controlled trial. Journal of Hepatology 75(1):46-54. link
This article is educational and does not constitute medical advice, diagnosis, or a treatment recommendation. Medication uses described as “off-label” are not licensed for that purpose in the UK and should only be considered under qualified clinical supervision. Always speak to your GP, pharmacist, or a registered specialist before starting, stopping, or changing any treatment. If you have severe or alarm symptoms - unintentional weight loss, blood in your stool, difficulty swallowing, persistent vomiting, a fever, or severe pain - seek urgent medical care.